Subsequently, considering that MEK 1/2 is a downstream EGFR pathway component, very often upregulated in resistance to therapies tumors [43], we decided to introduce the CTX in our study, widely considered as the standard of care of many HNSCC patients [44]. The gene discussed is MAP2K1; the disease is head and neck squamous cell carcinoma.